Randomised controlled trial of first-line tyrosine-kinase inhibitor (TKI) versus intercalated TKI with chemotherapy for EGFR -mutated nonsmall cell lung cancer.

Autor: Gijtenbeek RGP; Dept of Respiratory Medicine, Medical Centre Leeuwarden, Leeuwarden, The Netherlands., van der Noort V; Dept of Biometrics, Netherlands Cancer Institute - Antoni van Leeuwenhoek, Amsterdam, The Netherlands., Aerts JGJV; Dept of Pulmonary Diseases, Erasmus University Medical Centre, Rotterdam, The Netherlands., Staal-van den Brekel JA; Dept of Respiratory Medicine, Hospital Group Twente, Almelo/Hengelo, The Netherlands., Smit EF; Dept of Pulmonology, Leiden University Medical Centre, Leiden, The Netherlands., Krouwels FH; Dept of Respiratory Medicine, Spaarne Hospital, Hoofddorp, The Netherlands., Wilschut FA; Dept of Respiratory Medicine, Gelderse Vallei Hospital, Ede, The Netherlands., Hiltermann TJN; Dept of Pulmonary Diseases, University of Groningen and University Medical Centre Groningen, Groningen, The Netherlands., Timens W; Dept of Pathology and Medical Biology, University of Groningen and University Medical Centre Groningen, Groningen, The Netherlands., Schuuring E; Dept of Pathology and Medical Biology, University of Groningen and University Medical Centre Groningen, Groningen, The Netherlands., Janssen JDJ; Dept of Respiratory Medicine, Máxima Medical Centre, Eindhoven/Veldhoven, The Netherlands., Goosens M; Dept of Pulmonary Medicine, Gelre Hospitals, Zutphen, The Netherlands., van den Berg PM; Dept of Respiratory Medicine, Maasstad Hospital, Rotterdam, The Netherlands., de Langen AJ; Dept of Thoracic Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Stigt JA; Dept of Respiratory Medicine, Isala Hospital, Zwolle, The Netherlands., van den Borne BEEM; Dept of Pulmonary Diseases, Catharina Hospital, Eindhoven, The Netherlands., Groen HJM; Dept of Pulmonary Diseases, University of Groningen and University Medical Centre Groningen, Groningen, The Netherlands., van Geffen WH; Dept of Respiratory Medicine, Medical Centre Leeuwarden, Leeuwarden, The Netherlands., van der Wekken AJ; Dept of Pulmonary Diseases, University of Groningen and University Medical Centre Groningen, Groningen, The Netherlands.

Publikováno v: ERJ open research [ERJ Open Res] 2022 Oct 17; Vol. 8 (4). Date of Electronic Publication: 2022 Oct 17 (Print Publication: 2022).

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Cost-effectiveness of adding granulocyte colony-stimulating factor to primary prophylaxis with antibiotics in small-cell lung cancer.

Autor: Timmer-Bonte JN; 452 Department of Medical Oncology, Radboud University Nijmegen Medical Centre, PO Box 9101, 6500 HB Nijmegen, Netherlands. J.Timmer@onco.umcn.nl, Adang EM, Smit HJ, Biesma B, Wilschut FA, Bootsma GP, de Boo TM, Tjan-Heijnen VC

Publikováno v: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2006 Jul 01; Vol. 24 (19), pp. 2991-7. Date of Electronic Publication: 2006 May 08.

Post‐ictal diffuse alveolar haemorrhage: clinical profile based on case reports.

Autor: You, Jee Young¹ (AUTHOR) youj2@ccf.org, Stoller, James² (AUTHOR)

Publikováno v: Respirology Case Reports. May2022, Vol. 10 Issue 5, p1-5. 5p.

Antibiotic use is a negative predictor of the efficacy and toxicity of epidermal growth factor receptor-targeted therapy in advanced non-small cell lung cancer.

Autor: Liu, Kejun¹ (AUTHOR), Zhang, Weiwei² (AUTHOR), Tan, Qinquan¹ (AUTHOR), Jiang, Guanming¹ (AUTHOR) jiwen6465@126.com, Jia, Jun¹ (AUTHOR) jiwen6465@126.com

Publikováno v: Oncology Letters. Sep2019, Vol. 18 Issue 3, p2677-2683. 7p.